Nonalcoholic fatty liver disease is becoming the leading cause of disease resulting in liver transplantation (LT). As a result of this trend, more LT candidates are presenting with prior history of bariatric surgery (BS). Over the last decade, 960 patients underwent LT at our institution; 11 (1.1%) had prior BS. The most common type of BS was Roux-en-Y gastric bypass (n 5 9) with 1 sleeve gastrectomy and 1 jejunoileal bypass. A total of 9 patients underwent LT alone, and 2 underwent simultaneous liver-kidney transplantation. The most common indication for LT was nonalcoholic steatohepatitis (n 5 10) with 5 having additional diagnosis of alcoholic liver disease. The 30-day reoperation rate was 36.4% (n 5 4); indications were bile duct repair (n 5 3) and wound repair (n 5 1). In the first 6 months after LT, biliary complications were seen in 54.5% (n 5 6) of the patients. Both patient and graft survival rates at 1 and 2 years were 81.8% (n 5 9) and 72.7% (n 5 8), respectively. A total of 8 patients (72.7%) had indications for liver biopsy after LT; significant macrovesicular steatosis was found in 2 (18.2%). In patients with a history of alcohol consumption, 2 (40.0%) relapsed after LT. Two patients (18.2%) had a history of diet-controlled diabetes before LT; 1 of these patients became insulin dependent after LT. Mean body mass index (BMI) at LT was 31.0 6 5.7 kg/m 2 . Mean BMI at 1, 6, and 12 months after LT was 28.3 6 5.8, 28.0 6 3.2, and 31.0 6 6.6 kg/m 2 , respectively. Mean preoperative albumin was 2.6 6 0.6 mg/dL. Patients showed improvement in albumin after LT, with mean albumin of 2.7 6 0.6 and 3.2 6 0.5 mg/dL at 1 and 3 months, respectively. The liver profile was stable after LT, with mean aspartate aminotransferase of 32.9 6 18.4 and 26.6 6 19.8 IU/L and alanine aminotransferase of 28.0 6 17.5 and 30.2 6 17.0 IU/L at 6 and 12 months, respectively. In conclusion, outcomes of LT patients with prior BS are comparable with other transplant recipients with regards to patient and graft survival and post-LT complication rates.
A change in this trend is anticipated because over the past 2 decades, the number of patients with nonalcoholic fatty liver disease (NAFLD) leading to cirrhosis and end-stage liver disease has increased. (2) Nonalcoholic steatohepatitis (NASH) is projected to replace hepatitis C virus as the leading cause of newly diagnosed cirrhosis in the near future. (3) This change is due in part to a steady rise in diabetes and obesity in the United States, leading to NAFLD and NASH, combined with a stabilization in the prevalence of hepatitis C virus due to highly effective direct-acting antiviral treatments. (4) Recent data suggest that NASH cirrhosis is the second leading etiology of liver disease among adults on the LT waiting list in the United States, with a 170% increase between 2004 and 2013. (5) Patients with NASH are frequently overweight, and many have risk factors of metabolic syndrome such as hypertension, dyslipidemia, and impaired glucose tolerance. Despite recommendations of lifestyle changes including dietary changes and weight loss, a number of patients will be unsuccessful at achieving meaningful, sustained weight loss goals. Management of morbid obesity that is unresponsive to the above interventions includes bariatric surgery (BS). (6, 7) With careful patient selection, BS can be completed successfully for patients with NASH or NASH cirrhosis. (7) Numerous studies have shown BS to be effective in improving features of metabolic syndrome as well as reversing the histopathological features of NAFLD with some patients even experiencing complete resolution of the disease, thus limiting the need for LT. (8) (9) (10) However, for patients with decompensated cirrhosis and end-stage liver disease, or patients who develop early stage hepatocellular carcinoma, LT is the best option for longterm survival. There remains a limited understanding of surgical and medical outcomes after LT in the context of prior BS. We aimed to describe our patient outcomes after LT in patients with a prior history of BS.
Patients and Methods
A single-center retrospective analysis was performed on all patients who underwent LT at Henry Ford Hospital, between January 2006 and December 2015, to identify those with a history of BS. Patients with simultaneous liver-kidney transplantation were included. Patients with multivisceral transplantation and living donor LT were excluded. Our body mass index (BMI) cutoff for patients who undergo LT is 40 kg/m 2 ; anyone with a higher value is given recommendations for weight loss. The only exception is if a significant part of the excess weight is due to ascites or anasarca. Demographic, laboratory, clinical, and surgical data were collected. Clinical data obtained at the time of transplant included age at transplant, sex, primary liver disease, comorbidities, BMI, Model for End-Stage Liver Disease (MELD) score, and history of alcohol abuse. Laboratory data such as liver profile, renal profile, and coagulation profile were recorded. Data regarding weight loss surgery including timing of surgery and type of weight loss procedure were noted. Intraoperative data such as operating time, cold ischemia time, warm ischemia time, intraoperative transfusion, blood loss, and type of biliary anastomosis were collected. Postoperative data such as length of hospital stay and details on complications and their management were noted. Histologic data were collected if a postoperative liver biopsy was performed. Descriptive statistics were used to report clinical data and outcomes. Survival curve analysis and log-rank test were performed to compare our overall graft and patient survival to the cohort group. A P value < 0.05 was considered significant. This study was carried out after obtaining prior approval from the institutional review board and clearance from the ethics committee.
Results
Out of a total of 960 patients who underwent LT between January 2006 and December 2015 in our institution, 11 (1.1%) had a prior history of BS. There was a slight female predominance (54.5%). The most common type of BS was Roux-en-Y gastric bypass surgery (n 5 9) with 1 patient undergoing a sleeve gastrectomy and the other undergoing a jejunoileal bypass. Most of the patients underwent transplantation in recent years, ie, only 3 patients underwent LT between 2006 and 2010 and 8 patients (72.7%) underwent LT between 2011 and 2015. The mean interval between BS and LT was 11.6 6 11.0 years. The mean age at transplant was 51.3 6 9.0 years. A total of 9 patients underwent LT alone, and 2 underwent simultaneous liver-kidney transplantation. The most common indication for LT was NASH (90.9%) with 5 (45.5%) having a secondary diagnosis of alcoholic liver disease. One patient underwent LT for acute liver failure of unknown origin; he had previously undergone a Roux-en-Y gastric bypass surgery. The median preoperative total bilirubin was 5.7 6 4.2 mg/dL, aspartate aminotransferase (AST) was 415.1 6 1161.8 IU/L, alanine aminotransferase (ALT) was 489.4 6 1513.7 IU/L, serum creatinine was 1.7 6 0.8 mg/dL, and international normalized ratio was 2.3 6 0.5. The mean MELD score at the time of LT was 28.4 6 6.7. These were all native MELD scores, and none of the patients received exception/additional MELD points.
All patients received their organs from brain dead donors except for 1 who received an organ from a donation after circulatory death donor. Mean operating time was 405.8 6 111.5 minutes. The median cold ischemia time and warm ischemia time were 315.7 6 115.5 minutes and 35.9 6 8.6 minutes, respectively. Intraoperative median blood loss was 2423.0 6 1845.8 mL. Mean intraoperative packed red cell transfusion was 6.7 6 3.3 units. All patients received a duct-to-duct biliary anastomosis, and none required a Roux-en-Y hepaticojejunostomy. Mean posttransplant length of stay was 10.9 6 5.8 days. The 30-day reoperation rate was 36.4% (n 5 4); indications included laparotomy for bile leak (n 5 3) and wound dehiscence (n 5 1; Table 1 ). In the first 6 months after LT, the most common complications were biliary strictures/ leaks (n 5 6; Table 2 ). The patients with strictures were managed by stent (n 5 2) and percutaneous biliary drainage tube (n 5 1) placement. Biliary access via endoscopic retrograde cholangiopancreatography was completed without difficulty with the exception of 1 patient in whom removal of the stent placed during LT was laborious.
Mean follow-up after transplantation was 46.6 6 34.7 months. Both patient and graft survival rates at 1 and 2 years were 81.8% (n 5 9) and 72.7% (n 5 8), respectively. This was not statistically different to our overall patient survival of 88.5% and 84.1% at 1 and 2 years, respectively (P 5 0.88), and graft survival of 85.6% and 80.6% at 1 and 2 years, respectively (P 5 0.91). During the follow-up period, there were 3 deaths. A total of 2 recipients died within a year after transplant: 1 due to severe macrovesicular steatosis from alcohol relapse leading to liver failure and the other from ischemic cholangiopathy and sepsis possibly due to the increased risk of a donation after circulatory death donor organ. The third patient died 2 years after transplantation from central line-associated sepsis and renal failure. A total of 8 (72.7%) patients had indications for liver biopsy after LT; 2 (18.2%) showed significant macrovesicular steatosis. Among the 5 patients who had a known history of alcoholic liver disease pretransplant, 2 (40.0%) relapsed to alcohol after transplant. One, as described earlier, developed severe macrovesicular steatosis leading to liver failure and death within the first year after transplant. The other patient has been lost to follow-up. One patient underwent a jejunoileal bypass 27 years prior to LT.
He underwent reversal of the bypass procedure 4 months after transplant but subsequently required a sleeve gastrectomy 7 years later.
Despite a tendency toward weight gain in this population of patients with a history of NASH and often metabolic syndrome, their pretransplant and posttransplant weights were fairly stable at 1 year. The mean BMI at LT was 31.0 6 5.7 kg/m 2 . Mean BMI at 1, 6, and 12 months after LT was 28.3 6 5.8, 28.0 6 3.2, and 31.0 6 6.6 kg/m 2 , respectively. Two (18.2%) patients had a history of diabetes pre-LT that was diet-controlled; 1 became insulin dependent after LT. Liver function also showed improvement after transplantation and overall excellent graft function. Mean preoperative albumin was 2.6 6 0.6 mg/dL. Patients showed an improvement in their albumin after LT with a mean albumin of 2.7 6 0.6 and 3.2 6 0.5 mg/ dL at 1 and 3 months, respectively. Liver profile was stable after LT with a mean AST of 32. 
Discussion
Obesity is on the rise resulting in more people developing liver disease as a result of metabolic syndrome. (11) Increased rates of patients are presenting with NAFLD and are requiring LT. (12, 13) The prevalence estimates for NASH-related cirrhosis as an indication for LT, although already quite high, are likely underestimated due to the majority of cryptogenic cirrhosis actually constituting unrecognized NASH. (14, 15) Because of this, more patients are bound to present with a prior weight reduction surgery. Obesity in general has been recognized to negatively impact morbidity and mortality after major surgical procedures. (16) This is similarly found in the case of solid organ transplantations such as LT. (17) Previous studies have analyzed outcomes in obese patients who underwent LT. Conzen et al. reported that morbid obesity adversely affects longterm outcomes despite providing similar short-term results. (18) LaMattina et al. found that obesity was significantly associated with prolonged mean operative time, intensive care unit stay, increased transfusion requirements, infections, biliary complications, and decreased patient survival. (19) Two other groups, using both United Network for Organ Sharing and United Kingdom data, reported similarly worse outcomes in obese patients with higher rates of graft dysfunction, cardiovascular adverse events, and perioperative morbidity due to infectious complications and longer hospital stays as compared with normal-weight patients. (17, 20) Hence, many centers consider a BMI > 40 kg/m 2 to be a relative contraindication for transplantation. (21) However, another smaller study of 230 LT patients found no significant differences in perioperative morbidity and mortality between patients when stratified by BMI into a lean group (BMI 5 20-26 kg/m 2 ) and an obese group (BMI > 38 kg/m 2 ). (22) A meta-analysis by Saab et al. also identified that BMI did not specifically impact patient survival after transplant. (23) They suggested that comorbidities such as hypertension, hyperlipidemia, cardiovascular disease, and diabetes might have a higher impact on survival than obesity. A large group study looking at more than 15,000 adults from the National Health and Nutrition Examination Survey examined mortality risk with central obesity and BMI. (24) In their analysis, waist-to-hip ratio was a better outcome predictor than BMI. Similarly, in clinical practice, it has been observed that patients with metabolic profiles and central obesity at far lower BMIs may be more difficult to manage during and after LT than patients with BMIs over 40 kg/m 2 with no metabolic complications. There are also studies that indicate that obesity may be protective against postoperative mortality and morbidity in some conditions. (25, 26) In patients with advanced liver disease, a study by Karagozian et al. found that obese patients with cirrhosis had a lower inpatient mortality than nonobese patients. (27) Recent studies have also recognized that other more nuanced factors relating to habitus and debility, such as frailty, sarcopenia, and visceral adiposity are associated with an increased risk of poor outcomes in patients with cirrhosis. (28) (29) (30) These reports give us a glimpse into the problem, and more studies are required to truly understand these risks.
Operating on the obese individual may add additional technical challenges. In particular, one potential challenge is the history of a BS. Hence, in evaluating the patient from a surgical standpoint, consideration must be given to the potential for the following: adhesions, distortions of bowel continuity complicating biliary reconstruction, inability to easily access the native bile duct via endoscopic retrograde cholangiopancreatography, and potential for nutritional deficiencies perpetuated by a bypass procedure (including the possibility of contribution of the bypass to liver disease if not reversed, such as in jejunoileal bypass). Our experience suggests that surgeons should have an understanding of the particular BS procedure performed; in addition, during LT the surgeon should consider the possibility of difficult biliary access when determining the best method of biliary reconstruction including the possibility of facilitating access to the biliary system postoperatively (for example, placement of a stent or access loop).
Performing an elective or emergent surgery in a patient with cirrhosis is associated with increased potential morbidity and mortality. (31) Lopez-Delgado et al. showed that there was an increased risk of poor outcome in any patients with liver cirrhosis who undergo abdominal surgery. (32) BS and the type performed in itself also has an effect on a patient's liver. A recent prospective study by Billeter et al. showed that in obese patients with NAFLD, sleeve gastrectomy was superior to Roux-en-Y gastric bypass surgery. (33) Sleeve gastrectomy resulted in improvement of the transaminases 12 months after surgery compared with Roux-en-Y gastric bypass and normalized elevated ALT levels completely in these patients. Sleeve gastrectomy also helped in achieving improved highdensity lipoprotein levels and lower serum triglyceride levels compared with Roux-en-Y gastric bypass. Jejunoileal bypass, another type of bariatric procedure, is no longer used in the management of obesity as it can lead to liver failure. (34) One patient in our study underwent a jejunoileal bypass leading to liver failure and transplantation after 27 years after bypass. These studies show that the type of BS is extremely important because it can alter the liver disease and liver function. In addition, the nutritional deficiencies induced by BS and their subtle or overt impact on a liver allograft are poorly understood and require further study.
Additional concern in the obese transplant population includes the possibility of recurrence of NASH. El Atrache et al. showed that nearly 43% of patients with metabolic syndrome developed recurrence of NASH after transplant. (35) History of hypertension and the usage of insulin after transplant were factors found to be associated with NASH recurrence in this patient population. Yalamanchili et al. reported increased incidence of steatosis and fibrosis in patients who underwent LT with their indication being NASH and NAFLD. They had observed that the probability of developing hepatic steatosis 1, 2, 5, and 10 years after LT was 8.2%, 13.6%, 24.9%, and 32.9%, respectively. They noted that the probability of remaining free of steatosis was lower in patients who had a pretransplant diagnosis of NASH than in those with cryptogenic cirrhosis or another indication for transplantation. They also found that the actuarial probability of fibrosis at 5 and 10 years was greater in patients who developed NASH after transplant than in those who developed steatosis alone or never had fat demonstrated by liver biopsy during follow-up. (36) Some patients may develop metabolic syndrome and NAFLD even if their initial liver failure was due to a different cause. (37, 38) Because of the possibility of both recurrent and de novo fatty liver disease leading to cirrhosis in the transplanted liver, considering simultaneous BS and LT might be beneficial in select patients. Heimbach et al. found that combined LT plus sleeve gastrectomy resulted in effective weight loss and was associated with fewer post-LT metabolic complications compared with LT alone. (39) There are no studies comparing which type of BS might be superior to be performed at the time of LT. Gastric bypass is considered the gold standard for BS in the United States because it offers more significant and steady weight loss with resolution of comorbidities via restrictive, malabsorptive, and neurohormonal means compared with other types of BS. (40, 41) Sleeve gastrectomy is technically less complex and offers the absence of malabsorption, which may influence early posttransplant tacrolimus levels. (42) There is a chance of an anastomotic leak with either procedure, but a gastric leak in the case of sleeve gastrectomy takes longer to heal and may lead to more severe complications compromising the outcome of LT. (43) Posttransplant BS can also be considered, but it is associated with increased technical difficulties due to adhesions and complications relating to immunosuppression. (44, 45) Biliary complications are the most common source of morbidity after LT. Most series have incidences that range from 5% to 25%. (46) A national registry study performed in 2014 states 15% as the overall early biliary complication rate. (47) Late biliary complication rates in most centers range from 5% to 20%. (48) Overall, the rate for biliary complications that require interventions in this series is higher (55%) than our institutional rate, which is approximately 20%-25%. Also, most of the complications occurred months after transplantation as the 30-day biliary complication rate was only 18% (n 5 2). Of the remaining patients, 1 received a liver from a donation after cardiac death donor and developed bile duct necrosis and ischemic cholangiopathy 1 month after LT. A total of 2 patients developed delayed strictures at 4 and 6 months after surgery, and 1 patient developed a bile leak at 1 month after LT, which was drained through computed tomography guidance. Another factor that could have played a role in the high rate of biliary complications is biliary anastomosis technique. We developed and implemented a standardization in biliary anastomosis technique since 2013 and noted that our complication rate has been significantly lower at 23% compared with 37% prior to standardization. Most of the patients with biliary complications in this series underwent transplantation prior to standardization (n 5 4).
Most of the patients in our study had a long interval between BS and LT. Although we do not know the factors why, we speculate that this may be due to earlier recognition of the need for BS in obese patients. It could also be due to the improved understanding of increased surgical morbidity and mortality in decompensated cirrhosis.
In our study, we observed that posttransplant complications and survival among patients with a prior BS were similar in comparison to the general transplant population. Notably, we did not observe an increase in body weight after transplant for these patients. An improvement in liver function and good graft function after transplant was noted. Our study demonstrates that even though LT in patients with a prior BS may present technical challenges, the outcomes are similar in comparison to the general transplant population. This is a single-center study limited by the size of the cohort and retrospective nature. Data on the patients at the time of BS are limited because most of them were performed at other centers and close to a decade before LT (the mean interval between BS and transplant was 11 years). Hence, we do not have details regarding BMI or hepatic fibrosis at the time of BS and its progression.
Limited literature exists on LT and BS. Most are small case series. Many reports exist on BS performed after LT, but only 1 study, Lin et al., reported on a pretransplant history of BS. (49) Lin et al. reviewed 6 patients, all of whom underwent a laparoscopic sleeve gastrectomy prior to transplant. (49) The aim of their study was to analyze the safety and efficacy of laparoscopic sleeve gastrectomy in pretransplant candidates. As far as we know, our study is the first to report on the outcome of LT in patients with a prior BS.
In conclusion, the outcomes of LT in patients with prior history of BS are comparable with other transplant recipients with regards to patient and graft survival and posttransplant complication rates. Larger studies are needed to look into the effect of BS on the outcomes of LT including comparison among the various types of weight reduction operations. Longterm metabolic effects of transplant recipients for NASH with a history of BS compared with those without a history of BS also warrants future study with larger series.
